Janone inc. acquires an option for the rights to a worldwide, exclusive license for a novel strategy for treating methamphetamine use disorder

Las vegas, dec. 7, 2021 /prnewswire/ -- janone inc. (nasdaq: jan), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - today announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the translocator protein 18 kda (tspo).  the agreement with lsu health shreveport, along with other intellectual property relating to tspo's role in treating meth use disorder (mud), provides janone inc. with an opportunity to identify new drugs to enhance tspo activity, and by doing so, reducing craving for meth.
JAN Ratings Summary
JAN Quant Ranking